Daptomycin Hospira

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
06-04-2022
Produktets egenskaber Produktets egenskaber (SPC)
06-04-2022

Aktiv bestanddel:

daptomycin

Tilgængelig fra:

Pfizer Europe MA EEIG

ATC-kode:

J01XX09

INN (International Name):

daptomycin

Terapeutisk gruppe:

Antibacterials for systemic use,

Terapeutisk område:

Soft Tissue Infections; Skin Diseases, Bacterial

Terapeutiske indikationer:

Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Produkt oversigt:

Revision: 13

Autorisation status:

Authorised

Autorisation dato:

2017-03-22

Indlægsseddel

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPTOMYCIN HOSPIRA 350 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION
daptomycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Daptomycin Hospira is and what it is used for
2.
What you need to know before you are given Daptomycin Hospira
3.
How Daptomycin Hospira is given
4.
Possible side effects
5.
How to store Daptomycin Hospira
6.
Contents of the pack and other information
1.
WHAT DAPTOMYCIN HOSPIRA IS AND WHAT IT IS USED FOR
The active substance in Daptomycin Hospira powder for solution for
injection/infusion is daptomycin.
Daptomycin is an antibacterial that can stop the growth of certain
bacteria. Daptomycin Hospira is used in
adults and in children and adolescents (age from 1 to 17 years) to
treat infections of the skin and the
tissues below the skin. It is also used to treat infections in the
blood when associated with skin infection.
Daptomycin Hospira is also used in adults to treat infections in the
tissues that line the inside of the heart
(including heart valves) which are caused by a type of bacteria called
_Staphylococcus aureus._
It is also
used to treat infections in the blood caused by the same type of
bacteria when associated with heart
infection.
Depending on the type of infection(s) that you have, your doctor may
also prescribe other antibacterials
while you are receiving treatment with Daptomycin Hospira.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DAPTOMYCIN HOSPIRA
YOU SHOULD NOT BE GIVEN DAPTOMYCIN HOSPIRA
If 
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Daptomycin Hospira 500 mg powder for solution for injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Each vial contains 350 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 7 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Each vial contains 500 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 10 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Daptomycin is indicated for the treatment of the following infections
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with complicated
skin and soft-tissue infections
(cSSTI).
-
Adult patients with right-sided infective endocarditis (RIE) due to
_Staphylococcus aureus. _
It is
recommended that the decision to use daptomycin should take into
account the antibacterial
susceptibility of the organism and should be based on expert advice
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with
_ Staphylococcus aureus _
bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with
cSSTI, while in paediatric
patients, use in bacteraemia should be associated with cSSTI.
3
Daptomycin is active against Gram positive bacteria only (see section
5.1). In mixed infec
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel bulgarsk 06-04-2022
Produktets egenskaber Produktets egenskaber bulgarsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport bulgarsk 18-04-2018
Indlægsseddel Indlægsseddel spansk 06-04-2022
Produktets egenskaber Produktets egenskaber spansk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport spansk 18-04-2018
Indlægsseddel Indlægsseddel tjekkisk 06-04-2022
Produktets egenskaber Produktets egenskaber tjekkisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport tjekkisk 18-04-2018
Indlægsseddel Indlægsseddel dansk 06-04-2022
Produktets egenskaber Produktets egenskaber dansk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport dansk 18-04-2018
Indlægsseddel Indlægsseddel tysk 06-04-2022
Produktets egenskaber Produktets egenskaber tysk 06-04-2022
Indlægsseddel Indlægsseddel estisk 06-04-2022
Produktets egenskaber Produktets egenskaber estisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport estisk 18-04-2018
Indlægsseddel Indlægsseddel græsk 06-04-2022
Produktets egenskaber Produktets egenskaber græsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport græsk 18-04-2018
Indlægsseddel Indlægsseddel fransk 06-04-2022
Produktets egenskaber Produktets egenskaber fransk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport fransk 18-04-2018
Indlægsseddel Indlægsseddel italiensk 06-04-2022
Produktets egenskaber Produktets egenskaber italiensk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport italiensk 18-04-2018
Indlægsseddel Indlægsseddel lettisk 06-04-2022
Produktets egenskaber Produktets egenskaber lettisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport lettisk 18-04-2018
Indlægsseddel Indlægsseddel litauisk 06-04-2022
Produktets egenskaber Produktets egenskaber litauisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport litauisk 18-04-2018
Indlægsseddel Indlægsseddel ungarsk 06-04-2022
Produktets egenskaber Produktets egenskaber ungarsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport ungarsk 18-04-2018
Indlægsseddel Indlægsseddel maltesisk 06-04-2022
Produktets egenskaber Produktets egenskaber maltesisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport maltesisk 18-04-2018
Indlægsseddel Indlægsseddel hollandsk 06-04-2022
Produktets egenskaber Produktets egenskaber hollandsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport hollandsk 18-04-2018
Indlægsseddel Indlægsseddel polsk 06-04-2022
Produktets egenskaber Produktets egenskaber polsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport polsk 18-04-2018
Indlægsseddel Indlægsseddel portugisisk 06-04-2022
Produktets egenskaber Produktets egenskaber portugisisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport portugisisk 18-04-2018
Indlægsseddel Indlægsseddel rumænsk 06-04-2022
Produktets egenskaber Produktets egenskaber rumænsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport rumænsk 18-04-2018
Indlægsseddel Indlægsseddel slovakisk 06-04-2022
Produktets egenskaber Produktets egenskaber slovakisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport slovakisk 18-04-2018
Indlægsseddel Indlægsseddel slovensk 06-04-2022
Produktets egenskaber Produktets egenskaber slovensk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport slovensk 18-04-2018
Indlægsseddel Indlægsseddel finsk 06-04-2022
Produktets egenskaber Produktets egenskaber finsk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport finsk 18-04-2018
Indlægsseddel Indlægsseddel svensk 06-04-2022
Produktets egenskaber Produktets egenskaber svensk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport svensk 18-04-2018
Indlægsseddel Indlægsseddel norsk 06-04-2022
Produktets egenskaber Produktets egenskaber norsk 06-04-2022
Indlægsseddel Indlægsseddel islandsk 06-04-2022
Produktets egenskaber Produktets egenskaber islandsk 06-04-2022
Indlægsseddel Indlægsseddel kroatisk 06-04-2022
Produktets egenskaber Produktets egenskaber kroatisk 06-04-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport kroatisk 18-04-2018

Søg underretninger relateret til dette produkt